Please ensure Javascript is enabled for purposes of website accessibility

Valeant Pharmaceuticals Buying PreCision Dermatology for $475 Million

By Associated Press – Feb 3, 2014 at 11:28AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company could pay another $25 million if a certain sales target is reached.

NEW YORK (AP) -- Valeant Pharmaceuticals is looking to expand its skin care business by buying PreCision Dermatology for $475 million.

Cumberland, R.I.-based PreCision Dermatology makes treatments for skin ailments such as acne and atopic dermatitis, an itchy, chronic skin inflammation.

Valeant, which is based in Canada, said Monday that PreCision expects to have about $130 million in revenue in 2014. It said the purchase should close by the end of June and will add to its adjusted earnings immediately.

Valeant hasn't reported its full 2013 results, but has forecast $5.7 billion to $5.9 billion in revenue for the year.

The company could pay another $25 million if a certain sales target is reached.

The stock has doubled over the past 12 months.

The Motley Fool recommends Valeant Pharmaceuticals. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Related Articles

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.